Komboglyze (Metformin Hydrochloride, Saxagliptin)

Komboglyze is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder that requires glycaemic control.

• Type 2 diabetes mellitus: lowers blood glucose levels and improves HbA1c when used with diet and exercise.
• Inadequate control on metformin alone: adds saxagliptin to achieve target glycaemic goals.
• Adjunct to lifestyle modification: supports diet and exercise in managing type 2 diabetes.

• Metformin reduces hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while saxagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin levels that augment glucose‑dependent insulin secretion and suppress glucagon release, together providing complementary glucose‑lowering effects.

Komboglyze may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools.
• Headache: transient cranial discomfort.
• Upper respiratory tract infection: mild cold‑like symptoms.
• Abdominal pain: intermittent discomfort.
• Vomiting: occasional episodes.

Serious or Rare Side Effects

• Lactic acidosis: rare but potentially fatal metabolic disturbance.
• Pancreatitis: severe abdominal pain with elevated enzymes.
• Severe hypersensitivity: rash, angioedema, or anaphylaxis.
• Hepatic failure: signs of liver dysfunction.
• Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness, sweating, confusion.
• Renal impairment: worsening kidney function.

Before initiating Komboglyze, clinicians should evaluate patient-specific risk factors and monitor relevant clinical parameters.

• Renal function assessment: avoid in severe renal impairment.
• Hepatic function monitoring: use caution in patients with liver disease.
• Lactic acidosis risk: discontinue if signs of metabolic acidosis appear.
• Hypoglycaemia potential: monitor when combined with insulin or sulfonylureas.
• Pregnancy and lactation: assess risk‑benefit, as safety data are limited.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Komboglyze can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate lactic acidosis in patients with renal dysfunction.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase saxagliptin exposure.
• Insulin secretagogues (e.g., sulfonylureas): heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and potassium.
• Warfarin: occasional alteration of INR, require periodic monitoring.
• Beta‑blockers: may mask hypoglycaemia symptoms.
• Alcohol: can potentiate metformin‑related lactic acidosis.